Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-11 pm EDT			5-day change	1st Jan Change
468.85 ^USD	-2.23%		+2.01%	+16.43%

Jul. 07	RBC Raises Price Target on Vertex Pharmaceuticals to $430 From $420, Keeps Sector Perform Rating	MT
Jul. 03	Vertex Says Long-Term Data Show Casgevy's 'Durable' Clinical Benefits in Blood Disorder Trials	MT

Vertex Pharmaceuticals Incorporated Presents at American Diabetes Association 85th Scientific Sessions, Jun-20-2025 07:15 PM

Published on 06/20/2025 at 21:55, updated on 06/30/2025 at 17:52

Presenter Speech
Susie Lisa (Executives)

Thanks for your patience. Good evening, everyone. My name is Susie Lisa, and I'm the Senior Vice President of Investor Relations for Vertex Pharmaceuticals.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Vertex Pharmaceuticals Incorporated

RBC Raises Price Target on Vertex Pharmaceuticals to $430 From $420, Keeps Sector Perform Rating	Jul. 07	MT
Vertex Says Long-Term Data Show Casgevy's 'Durable' Clinical Benefits in Blood Disorder Trials	Jul. 03	MT
Vertex Pharmaceuticals Presents Longer-Term Data at the 2025 European Hematology Association Congress Demonstrating Durability of CASGEVY®? and Provides Update on Expanding Global Access to CASGEVY	Jul. 03	CI
Vertex Pharmaceuticals Announces European Commission Approval of ALYFTREK, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis	Jul. 01	CI
EU approves Vertex's next-generation cystic fibrosis drug	Jul. 01	RE
EU approves Vertex's next-generation cystic fibrosis drug	Jul. 01	RE
Vertex Pharmaceuticals Says European Commission Approves Alyftrek for Treating Cystic Fibrosis	Jul. 01	MT
Vertex's next-generation cystic fibrosis drug gets EU approval	Jul. 01	RE
Vertex Pharmaceuticals Incorporated Presents at American Diabetes Association 85th Scientific Sessions, Jun-20-2025 07:15 PM	Jun. 30
AbbVie to buy Capstan for up to $2.1 billion in immunology push	Jun. 30	RE
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) added to Russell 1000 Dynamic Index	Jun. 30	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Value-Defensive Index	Jun. 30	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000E Value Index	Jun. 29	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000 Value Index	Jun. 29	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell Top 200 Value Index	Jun. 29	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Value Index	Jun. 29	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell Top 200 Value Benchmark	Jun. 29	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000E Value Benchmark	Jun. 29	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 3000 Value Benchmark	Jun. 29	CI
Vertex Pharmaceuticals Incorporated(NasdaqGS:VRTX) dropped from Russell 1000 Value Benchmark	Jun. 29	CI
Vertex Pharmaceuticals Incorporated and Ono Pharmaceutical Co., Ltd. Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea	Jun. 23	CI
Vertex Pharmaceuticals, Ono Sign License Deal for Povetacicept in Japan, South Korea	Jun. 23	MT
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $460 From $464	Jun. 20	MT
RBC Capital Adjusts PT on Vertex Pharmaceuticals to $420 From $423, Maintains Sector Perform Rating	Jun. 17	MT
Saudi Arabia Signs Multiple Healthcare Deals, Partnerships at BIO 2025	Jun. 17	MT